Related Experiment Video
Updated: Oct 17, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
Shuluan Li1, Pei Zhang2, Tianyu Wang3
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Abstract:
The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK-positive lung squamous cell carcinoma. The patient in this report was diagnosed with ALK-positive lung squamous cell carcinoma with brain metastases, and received brigatinib after failure of first-line chemotherapy. Response duration was approximately 11 months, with tolerable side effects. In conclusion, a good clinical effect was achieved in a patient with ALK positive lung squamous cell carcinoma who received treatment with an ALK inhibitor.
Insights
Brigatinib shows therapeutic effect in ALK-positive lung squamous cell carcinoma (sqCC). This anaplastic lymphoma kinase inhibitor demonstrated a good clinical response in a patient with brain metastases after chemotherapy failure.
Area of Science:
- Oncology
- Pharmacology
Background:
- Anaplastic lymphoma kinase (ALK) inhibitors are crucial in treating certain cancers.
- The efficacy of ALK inhibitors in ALK-positive lung squamous cell carcinoma (sqCC) is not definitively established.
Observation:
- A patient with ALK-positive lung squamous cell carcinoma and brain metastases was treated with brigatinib.
- This treatment was administered after the patient's failure to respond to first-line chemotherapy.
Findings:
- Brigatinib demonstrated a significant therapeutic effect in the patient.
- The response duration to brigatinib was approximately 11 months.
- The side effects experienced were tolerable.
Implications:
- This case suggests brigatinib may be a viable treatment option for ALK-positive sqCC.
- Further research is warranted to confirm the role of ALK inhibitors in this patient population.
- Targeted therapy with brigatinib offers a promising avenue for managing advanced ALK-positive lung squamous cell carcinoma.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019